Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.

Pathology international - 1 Dec 2017

Thiem Sebastian, Herold Thomas, Krafft Ulrich, Bremmer Felix, Tolkach Yuri, Szász Attila M, Kriegsmann Joerg, Gaisa Nadine T, Niedworok Christian, Szarvas Tibor, Reis Henning

Abstract excerpt

High rates of telomerase reverse transcriptase (TERT) promoter mutations have recently been described in urothelial carcinoma (UC). Unlike UC in the bladder, adenocarcinomas account for the majority of urachal cancer (UrC) cases. As data in UrC is unclear, we analyzed TERT promoter mutations in a large cohort of UrC for its differential diagnostic, clinicopathological and prognostic significance. UrC cases from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Carcinoma, Squamous Cell

Share to Cohort Studies

Share to Promoter Regions, Genetic

Share to Telomerase

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 29047227
DOI: 10.1111/pin.12594

Genes

TERT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.PMID 29047227Read ↗

Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.Semantic proximity Read ↗

Emerging targets in upper tract urothelial carcinomas: the TERT gene.Semantic proximity Read ↗

TERT promoter mutations and methylation for telomerase activation in urothelial carcinomas: New mechanistic insights and clinical significance.Semantic proximity Read ↗

Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.Semantic proximity Read ↗

Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.Semantic proximity Read ↗

High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.Semantic proximity Read ↗

Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.Semantic proximity Read ↗

TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinomaSemantic proximity Read ↗

Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.Semantic proximity Read ↗

Effect of the TERT mutation on the prognosis of patients with urothelial carcinoma: a systematic review and meta-analysis.Semantic proximity Read ↗

High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder.Semantic proximity Read ↗

Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.